At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Docetaxel 75mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Degarelix for Metastatic Prostatic Adenocarcinoma. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostatic Adenocarcinoma
CountriesUnited States
CollaboratorsFerring Pharmaceuticals
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionMar 2021
Study CompletionDec 2024
TodayJul 2026
First PostedMar 3, 2017
Enrollment StartMar 1, 2017
Primary CompletionMar 3, 2021
Study CompletionDec 11, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.3 years ago
Interventions
Docetaxeldrug
The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
Degarelixdrug
Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.